Sresan Pharma Under Investigation: Money Laundering and Deadly Syrup Concerns

India's financial crime-fighting agency is actively investigating seven locations tied to Sresan Pharma over suspicions of money laundering. Sources claim this is linked to the recent tragic deaths of 19 children in Madhya Pradesh, attributed to the company's contaminated cough syrup.

The cough syrup, banned after testing, revealed it contained toxic diethylene glycol levels far exceeding safety limits. Current searches in Chennai target accusations of laundering and involve the homes of senior Tamil Nadu drug control officials. Owner G. Ranganathan remains unreachable following his arrest last week.

India, a major player in the global pharmaceutical market, faces increased scrutiny after similar incidents abroad. While international regulations mandate rigorous syrup testing, domestic standards have been questioned, with WHO citing regulatory inconsistencies. Recent warnings also point to two more syrups, Respifresh and RELIFE, for similar violations.

(With inputs from agencies.)